荷商葛蘭素史克藥廠

“Science is giving us all these solutions to prevent disease before it even starts, but if we don't have the right policies in place to unlock funding, make access easy for people and build the belief, the right education, what does it matter?” Read The New York Times' interview with Kate Hashey, MA, MPH about how prioritizing #prevention and ensuring access to #vaccines for everyone is part of GSK’s vision to improve #publichealth around the globe 🌎➡️ https://gsk.to/3yog60x

#News for #investors and #media: Today we announced that we have entered into an agreement with Flagship Pioneering to discover future medicines and vaccines for patients. Find out more: https://gsk.to/3WkUgDj

Chronic hepatitis B is a long-lasting and potentially life-threatening liver infection caused by the hepatitis B virus. Even with the progress that has been made thanks to vaccination, CHB affects 257 million people around the world. We are inspired by Sophia - and people like her - to continue innovating in this space. That is why we are proud to partner with The World Hepatitis Alliance on this #WorldHepatitisDay to raise awareness of how much more needs to be done for those living with CHB. It is time for action to meet the needs of the people living with CHB.

“There are three things necessary to ending the HIV/AIDS epidemic,” says Dr Nneka Nwokolo, Head of Global Patient Engagement for ViiV Healthcare, our specialist HIV company. “One is to test everybody so that you identify people living with HIV. Second is to treat people who you find have HIV. And third is to prevent HIV from occurring in people who don’t have it. You cannot end HIV without all of them, and prevention is key.” 🔗 Find out what it means to change the course of disease through prevention: https://gsk.me/3SqOMWa #AIDS2024

At #AIDS2024, we are showcasing our latest innovation to develop the next generation of treatment and prevention options for people living with #HIV. By working together, we can limit the impact of HIV. Meet Tammeka, a change maker, innovator and equality advocate. Tammeka and her team are developing cutting-edge digital solutions to enable more inclusive clinical trials. Their groundbreaking research also includes transgender women in all-women studies, promoting inclusivity and creating a level playing field. Learn more about our goal to end HIV and explore career opportunities at https://gsk.to/4c3cfno #GSKCareers #WeAreGSK.

HIV remains one of the world’s biggest health epidemics, with 1.3 million new diagnoses annually, and more than 39 million people living with HIV. There is not yet a cure for HIV; however, 40 years of innovation has transformed HIV into a manageable, chronic health condition, enabling people living with HIV to lead long and healthy lives. Despite this progress, HIV stigma is still pervasive and impacts people living with HIV and their care. Our goal is to minimise the impact of HIV on people’s lives by treating and preventing the disease, and tackling HIV-related stigma. Find out more: https://gsk.to/3WFe2Le 👈 #AIDS2024

HIV remains one of the world’s biggest health threats and while great strides have been made in HIV treatment, with people living with HIV on effective treatment able to live long and full lives, stigma remains a challenge. Fear of harsh judgement and discrimination associated with HIV can prevent many people from getting tested and diagnosed, as well as starting and staying on treatment. Find out how we are committed to changing that, by minimising the impact of HIV on people’s lives through treatment, prevention and ultimately cure: 🔗 https://gsk.to/3SkUn0g 👈 #AIDS2024

HIV remains one of the world’s biggest health threats and while great strides have been made in HIV treatment, with people living with HIV on effective treatment able to live long and full lives, stigma remains a challenge.  

#News for #investors and #media: new data shared today at #AIDS2024 by our specialist HIV company, ViiV Healthcare, include updates from our pipeline that reinforce our leadership in HIV innovation and supporting the community. 🔗 Find out more: https://gsk.to/4cRI7MW

“There are three things necessary to ending the HIV/AIDS epidemic,” says Dr Nneka Nwokolo, Head of Global Patient Engagement for ViiV Healthcare, our specialist HIV company. “One is to test everybody so that you identify people living with HIV. Second is to treat people who you find have HIV. And third is to prevent HIV from occurring in people who don’t have it. You cannot end HIV without all of them, and prevention is key.” Find out what it means to change the course of disease through prevention 👇 #AIDS2024